Aspiriant LLC’s U.S. High Relative Profitability Portfolio ETF Class Shares DUHP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$994K Buy
23,712
+6,413
+37% +$269K 0.02% 173
2026
Q2
$722K Hold
17,299
– – 0.02% 207
2026
Q1
$636K Hold
17,299
– – 0.02% 191
2025
Q4
$658K Hold
17,299
– – 0.02% 193
2025
Q3
$653K Hold
17,299
– – 0.02% 182
2025
Q2
$615K Sell
17,299
-807
-4% -$26.9K 0.02% 183
2025
Q1
$600K Buy
18,106
+807
+5% +$27.7K 0.02% 174
2024
Q4
$585K Hold
17,299
– – 0.02% 176
2024
Q3
$589K Hold
17,299
– – 0.02% 179
2024
Q2
$553K Hold
17,299
– – 0.02% 187
2024
Q1
$547K Hold
17,299
– – 0.02% 188
2023
Q4
$495K Hold
17,299
– – 0.02% 190
2023
Q3
$444K Hold
17,299
– – 0.02% 190
2023
Q2
$459K Hold
17,299
– – 0.02% 187
2023
Q1
$435K Buy
+17,299
New +$428K 0.02% 191

Other funds holding DUHP

Aspiriant LLC's DUHP Position: Q3 2026 in Review

Aspiriant LLC increased its U.S. High Relative Profitability Portfolio ETF Class Shares (DUHP) stake by 37% in Q3 2026, buying an estimated $269K and bringing the position to 23,712 shares worth $994K. The position accounts for 0.02% of the portfolio, ranked #173.

Aspiriant LLC first reported a position in DUHP in Q1 2023 and has held it in 15 quarters since. 336 funds tracked by Wall St. Rank hold DUHP as of Q3 2026.

  • Aspiriant LLC held 23,712 shares of U.S. High Relative Profitability Portfolio ETF Class Shares worth $994K as of Q3 2026.
  • Aspiriant LLC bought 6,413 U.S. High Relative Profitability Portfolio ETF Class Shares shares in Q3 2026, an estimated $269K.
  • U.S. High Relative Profitability Portfolio ETF Class Shares made up 0.02% of Aspiriant LLC's portfolio in Q3 2026, its #173 holding.
  • Aspiriant LLC first reported a position in U.S. High Relative Profitability Portfolio ETF Class Shares in Q1 2023 and has held it in 15 quarters since.
  • 336 funds tracked by Wall St. Rank held U.S. High Relative Profitability Portfolio ETF Class Shares as of Q3 2026.

Based on Aspiriant LLC's 13F filing for Q3 2026, filed 16 Oct 2026.